癌症风险与传统合成抗风湿药物：一项叙述性综述。
Risk of cancer and conventional syntethic DMARDS: A narrative review.
作者信息
Skare Thelma, de Carvalho Jozélio Freire
机构信息
Department of Rheumatology, Hospital Evangélico Mackenzie, Curitiba, PR, Brazil.
Institute for Health Science, Federal University of Bahia, Salvador, Brazil.
出版信息
North Clin Istanb. 2025 Jun 19;12(3):378-384. doi: 10.14744/nci.2024.21976. eCollection 2025.
Abstract
Immunosuppressors and immunomodulators are widely used for the treatment of rheumatic diseases. Among them are the conventional Disease-Modifying Antirheumatic Drugs (DMARDs) such as methotrexate, azathioprine, antimalarials, cyclosporine, etc. These drugs can induce remission or control inflammation, improving patients' outcomes. Nevertheless, there is some concern that these drugs may have a carcinogenic potential, favoring the appearance of tumors. Herein, a narrative review of malignancy risk after using conventional DMARDs is done.
摘要
免疫抑制剂和免疫调节剂被广泛用于治疗风湿性疾病。其中包括传统的改善病情抗风湿药（DMARDs），如甲氨蝶呤、硫唑嘌呤、抗疟药、环孢素等。这些药物可以诱导缓解或控制炎症，改善患者的预后。然而，有人担心这些药物可能具有致癌潜力，会增加肿瘤出现的几率。在此，对使用传统DMARDs后的恶性肿瘤风险进行了叙述性综述。
相似文献
1
Risk of cancer and conventional syntethic DMARDS: A narrative review.癌症风险与传统合成抗风湿药物：一项叙述性综述。
North Clin Istanb. 2025 Jun 19;12(3):378-384. doi: 10.14744/nci.2024.21976. eCollection 2025.
3
Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.美国医疗保健研究与质量局（AHRQ）对用于青少年特发性关节炎患儿的改善病情抗风湿药的比较效果评价总结。
J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl B):1-16. doi: 10.18553/jmcp.2012.18.S1-B.1.
4
Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.成人非感染性中间、后和全葡萄膜炎的非生物制剂、皮质类固醇保留疗法。
Cochrane Database Syst Rev. 2022 Oct 31;10(10):CD014831. doi: 10.1002/14651858.CD014831.pub2.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
7
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
本文引用的文献
1
Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?环磷酰胺在早期严重快速进展性系统性硬化症中仍然是金标准吗？
Autoimmun Rev. 2024 Jan;23(1):103439. doi: 10.1016/j.autrev.2023.103439. Epub 2023 Sep 9.
2
Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: A study based on a Japanese medical claims database.类风湿关节炎患者接受甲氨蝶呤单药与联合治疗与普通人群相比恶性淋巴瘤的风险：基于日本医疗索赔数据库的研究。
Int J Clin Pharmacol Ther. 2023 Oct;61(10):430-436. doi: 10.5414/CP204372.
3
Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.类风湿关节炎患者甲氨蝶呤治疗后的淋巴组织增生性疾病风险。
Cancer Sci. 2023 Sep;114(9):3719-3727. doi: 10.1111/cas.15894. Epub 2023 Jun 26.
4
Systemic Sclerosis Association with Malignancy.系统性硬化症与恶性肿瘤的关系。
Clin Rev Allergy Immunol. 2022 Dec;63(3):398-416. doi: 10.1007/s12016-022-08930-4. Epub 2022 Sep 19.
5
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.类风湿关节炎患者起始甲氨蝶呤与羟氯喹治疗后恶性黑色素瘤和非黑色素瘤皮肤癌风险：一项队列研究。
Clin Exp Rheumatol. 2023 Jan;41(1):110-117. doi: 10.55563/clinexprheumatol/staplf. Epub 2022 May 10.
6
Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis-a case-control study.系统性红斑狼疮中的血液系统恶性肿瘤：临床特征、危险因素和预后——一项病例对照研究。
Arthritis Res Ther. 2022 Jan 3;24(1):5. doi: 10.1186/s13075-021-02692-8.
7
Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.回顾性分析风湿性疾病患者中其他医源性免疫缺陷相关淋巴增生性疾病。
Br J Haematol. 2021 Nov;195(4):585-594. doi: 10.1111/bjh.17824. Epub 2021 Sep 23.
8
Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.抗疟药可能降低系统性红斑狼疮患者的癌症风险：前瞻性研究的系统评价和荟萃分析。
Ann Med. 2021 Dec;53(1):1687-1695. doi: 10.1080/07853890.2021.1981547.
9
Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.类风湿关节炎患者恶性肿瘤的患病率、发病率和危险因素：来自韩国的全国性队列研究。
Korean J Intern Med. 2023 Jan;38(1):113-124. doi: 10.3904/kjim.2021.146. Epub 2021 Aug 20.
10
Pharmacotherapy for Behçet's Disease and the Risk of Malignancy.白塞病的药物治疗与恶性肿瘤风险
Front Pharmacol. 2021 Jul 20;12:661150. doi: 10.3389/fphar.2021.661150. eCollection 2021.
Zotero 插件